Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
Mala Pande & Marsha L. Frazier
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Descriptive epidemiology: assessment of the distribution of colorectal cancer
Analytic epidemiology: assessment of determinants of colorectal cancer:
In the last decade, cancer has become the leading cause of death in economically developed countries and the second leading cause of death in developing countries. Globally, colorectal cancer (CRC) is the third most common cancer in men, the second most common cancer in women, and the fourth leading cause of cancer deaths. In 2008, an estimated 665,000 men and 570,000 women were diagnosed with CRC, and 668,000 deaths were attributable to CRC, accounting for 8% of all cancer deaths [1].
There is almost a 10-fold variation in CRC incidence rates (proportion of newly diagnosed cases per year) worldwide for both sexes. CRC incidence rates are highest in Australia/New Zealand and Western Europe and lowest in Middle Africa and South-Central Asia [1] (Figure 1.1).
Figure 1.1 Estimated age-standardized incidence rate per 100,000 colorectum: both sexes, all ages [1].
Although developed countries account for almost two-thirds of CRC cases (with the exception of a few countries in Eastern Europe, Eastern Asia, and Spain), the rates in developed countries have mostly remained stable or declined over time, whereas rates in developing countries are rising [1;2]. These differences may be attributable to changes in lifestyle and environmental factors as well as underlying genetic susceptibility. The rapid increase in the cancer burden in developing countries is possibly due to population growth and aging, and adverse lifestyle changes such as increased smoking, physical inactivity, and westernized diets [3]. Worldwide, the age-standardized rate (ASR) for CRC incidence is 17.3 per 100,000 population and the cumulative risk for CRC from birth to age 74 years is 0.9% [1]. The incidence of CRC is higher in men than in women (overall male:female ratio of age-standardized rates is 1.4:1). Country-specific rates for CRC incidence and mortality are available from the GLOBCAN database from the World Health Organization's International Agency for Research on Cancer (http://globocan.iarc.fr/).
It is estimated that 143,460 men and women (73,420 men and 70,040 women) will be diagnosed with CRC in the US in 2012 [4]. Of all CRCs diagnosed, about 72% affect the colon and the remaining 28% affect the rectum. Incidence rates for CRC in the US have declined roughly by 2–3% every year over the last 15–20 years [5], largely attributable to the advent of CRC screening, which allows for early detection and removal of precancerous polyps [6]. The lifetime incidence of CRC in the US is 5%, or 1 in 20 people are predicted to get CRC over their lifetime. The incidence of CRC is 25% higher in men than in women, and most (>90%) cases occur in men and women older than 50 years. Rates vary significantly by race/ethnicity; the incidence of CRC in African-American men is 20% higher than in white men [3].
CRC is the fourth most common cause of death from cancer, accounting for 8% of all cancer deaths worldwide. Globally, mortality rates continue to increase for deaths due to CRC (the ASR is 8.2/100,000). Cancer survival tends to be poorer in developing countries, possibly because cancer is diagnosed at later stages and patients have limited access to timely and standard care [3]. There is less variability in mortality rates worldwide (6 times higher in men and 5 times higher in women, in countries with the highest rates than in countries with the lowest rates), with the highest estimated mortality rates in both sexes in Central and Eastern Europe (20.1/100,000 for men and 12.2/100,000 for women), and the lowest in Middle Africa (3.5/100,000 for men and 2.7/100,000 for women) [1].
The mortality rate for CRC is roughly half the incidence rate, so its prognosis is relatively good. Thus, CRC has a high 5-year prevalence (number of cases in the population at a given time), with an estimated 3.26 million people alive with CRC diagnosed within the past 5 years [1;7]. The decrease in mortality may be due to changes in incidence, progress in therapy, improved early detection due to widespread screening, diagnosis at earlier stages (when the cancer is more amenable to treatment), and many other factors [8].
An estimated 51,690 people will die of CRC in 2012 [4]. CRC-related deaths in the US have been declining steadily from 1975 to 2009, with an annual percentage change of 0.5–4% [4]. The US mortality rate for CRC from 2005 to 2009 was 16.7 per 100,000 patients per year. However, mortality rates varied significantly by both sex and race/ethnicity. Mortality rates are highest for African-American men (29.8/100,000) and lowest for Asian-Pacific Islander women (9.6/100,000). The largest proportion (29%) of CRC deaths occurred in patients aged 75–84 years, and the median age at death was 74 years [4]. The mortality rate for CRC is roughly one-third the incidence rate, resulting in a high prevalence of patients diagnosed with CRC. On January 1, 2009, over 1.14 million people with a history of CRC were alive in the US [4]. The 5-year survival rate for CRC is related to the stage at diagnosis; CRC diagnosed at the local stage has a 5-year survival rate of 90%, but the rate drops to only 12% if CRC is diagnosed after it has metastasized [9]. Overall, the US has one of the highest 5-year survival rates for CRC in the world: 61% for patients diagnosed at any stage.
Epidemiologic studies have identified many factors that may increase or decrease risk of CRC. Some of these factors, such as a personal or family history of CRC or a history of inflammatory bowel disease, are non-modifiable, but many lifestyle risk factors, such as smoking, alcohol use, and lack of physical activity, are modifiable. It was recently reported that following a healthy lifestyle that includes being physically active for at least 30 minutes per day, following a healthy diet, controlling abdominal adiposity, not smoking, and not drinking alcohol in excess could have prevented 23% of the CRC cases in a cohort of more than 50,000 people aged 50–64 years, who were cancer-free at baseline and followed up for an average of 10 years [10]. Genetic susceptibility due to inherited germline mutations is the cause of CRC in about 5% of patients; however, most cases are sporadic, not familial.
Age is a major risk factor influencing CRC incidence and death rate, because both rates increase with age. Over...
Dateiformat: ePUBKopierschutz: Adobe-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet – also für „fließenden” Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein „harter” Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.Bitte beachten Sie: Wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!
Weitere Informationen finden Sie in unserer E-Book Hilfe.
Dateiformat: PDFKopierschutz: Adobe-DRM (Digital Rights Management)
Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein „harter” Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.
Bitte beachten Sie: Wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!